Marek Krogulec

1.7k total citations · 1 hit paper
10 papers, 675 citations indexed

About

Marek Krogulec is a scholar working on Rheumatology, Immunology and Economics and Econometrics. According to data from OpenAlex, Marek Krogulec has authored 10 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 6 papers in Immunology and 3 papers in Economics and Econometrics. Recurrent topics in Marek Krogulec's work include Rheumatoid Arthritis Research and Therapies (8 papers), Biosimilars and Bioanalytical Methods (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Marek Krogulec is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Biosimilars and Bioanalytical Methods (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Marek Krogulec collaborates with scholars based in United States, South Korea and Poland. Marek Krogulec's co-authors include William L. Macias, Josef S Smolen, Charles Ludivico, Scott D. Beattie, Terence Rooney, Omid Zamani, Joel Kremer, Tracy Cardillo, Stephanie de Bono and Mark C. Genovese and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Marek Krogulec

9 papers receiving 654 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baricitinib in Patients with Refractory Rheumatoid Arthritis

2016 458 citations Mark C. Genovese, Joel Kremer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marek Krogulec United States	6	493	244	194	160	134	10	675
Kahaku Emoto Japan	6	590 1.2×	293 1.2×	167 0.9×	194 1.2×	182 1.4×	9	827
Liliana Morales Argentina	2	469 1.0×	236 1.0×	134 0.7×	141 0.9×	144 1.1×	2	625
Sebastian Meerwein United States	8	524 1.1×	299 1.2×	158 0.8×	126 0.8×	193 1.4×	23	675
B. Combe France	13	638 1.3×	247 1.0×	301 1.6×	151 0.9×	77 0.6×	22	959
Paola Masolini Italy	17	165 0.3×	389 1.6×	157 0.8×	187 1.2×	294 2.2×	24	849
Coralie Poncet France	14	301 0.6×	98 0.4×	70 0.4×	93 0.6×	117 0.9×	55	526
Elaine Murray United States	9	104 0.2×	123 0.5×	200 1.0×	154 1.0×	198 1.5×	11	716
Alain Sadoun France	12	111 0.2×	432 1.8×	142 0.7×	209 1.3×	249 1.9×	28	820
Michael H. Brave United States	9	80 0.2×	178 0.7×	101 0.5×	126 0.8×	374 2.8×	15	664
Jiří Mayer Czechia	11	320 0.6×	748 3.1×	81 0.4×	679 4.2×	161 1.2×	48	1.0k

Countries citing papers authored by Marek Krogulec

Since Specialization

Citations

This map shows the geographic impact of Marek Krogulec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Krogulec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Krogulec more than expected).

Fields of papers citing papers by Marek Krogulec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Krogulec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Krogulec. The network helps show where Marek Krogulec may publish in the future.

Co-authorship network of co-authors of Marek Krogulec

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Krogulec. A scholar is included among the top collaborators of Marek Krogulec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Krogulec. Marek Krogulec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Burmester, Gerd R, Artur Racewicz, Janusz Jaworski, et al.. (2025). Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. Clinical Drug Investigation. 45(8). 551–563.

Lebwohl, Mark, John Koo, Janusz Jaworski, et al.. (2025). Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study. Advances in Therapy. 42(3). 1582–1599. 1 indexed citations

Smolen, Josef S, Artur Racewicz, Janusz Jaworski, et al.. (2024). Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 10(4). e004514–e004514. 3 indexed citations

Daïen, C., Marek Krogulec, Paul Gineste, et al.. (2022). Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Annals of the Rheumatic Diseases. 81(8). 1076–1084. 23 indexed citations

Kay, Jonathan, Janusz Jaworski, Rafał Wojciechowski, et al.. (2021). Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Research & Therapy. 23(1). 51–51. 22 indexed citations

Furst, Daniel E., Edward Keystone, Jonathan Kay, et al.. (2021). AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT. Annals of the Rheumatic Diseases. 80. 1123–1124. 2 indexed citations

Furst, Daniel E., Janusz Jaworski, Rafał Wojciechowski, et al.. (2021). Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Lara D. Veeken. 61(4). 1385–1395. 12 indexed citations

Genovese, Mark C., Joel Kremer, Omid Zamani, et al.. (2016). Baricitinib in Patients with Refractory Rheumatoid Arthritis. New England Journal of Medicine. 374(13). 1243–1252. 458 indexed citations breakdown →

Genovese, M. C., Joel M. Kremer, Omid Zamani, et al.. (2015). OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Annals of the Rheumatic Diseases. 74. 75–76. 20 indexed citations

10.

Emery, Paul, Oliver FitzGerald, Bernard Combe, et al.. (2014). Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 371(19). 1781–1792. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact